Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  CardiovascularIssue 730

AACE: Prediabetes Guidelines for Lipids and Blood Pressure Levels

Call for guidelines for prediabetes from the Clinical Endocrinologists meeting....

Advertisement

While the American Association of Clinical Endocrinologists (AACE) guidelines for diabetes prevention offer an HbA1c goal of normoglycemia when a patient is in the range of prediabetes, AACE presented a call for additional guidelines in lipids and blood pressure when treating patients with prediabetes.

Leigh Perreault, MD, associate professor of medicine at the University of Colorado Anschutz Medical Campus, stated during her presentation at the AACE 23rd Annual Scientific & Clinical Congress that, currently, "there are no guidelines anywhere for exactly what our goals should be for lipids or for blood pressure for these people." "We should come together as a community to create these guidelines because there are so many people out there who could probably benefit."

Perreault presented extensive data supporting the AACE guidelines that instruct physicians to aim for normoglycemia in patients with prediabetes. The Diabetes Prevention Program, she explained, showed that when patients in the range of prediabetes returned to normoglycemia at any given point over the 10 years of observation, their risk of transitioning to diabetes was reduced. If they returned to normoglycemia more than once, they further reduced their risk.

"If we set that goal as normal glucose regulation, we can reduce their risk tremendously, up to 70% for people in whom we can actually get them there and keep them there," Perreault said."The good news from this analysis is it didn't matter how people got to normal, as long as people got to normal. This is a change, a shift in our paradigm, a rethinking of diabetes care or diabetes prevention."

This shift should also encompass reducing the cardiovascular risk of these patients with prediabetes, she said.

"There are data showing we can reduce cardiovascular risk factors and cardiovascular risk in people with prediabetes by treating them," Perreault said. "People can get complications of diabetes even if they never develop diabetes. People with prediabetes can get these complications. And the prevention of diabetes, particularly if [normoglycemia] can be achieved, is key and the risk reduction of cardiovascular disease might be right behind it."

Therefore, there is need to consider the lipid profile and blood pressure levels and create guidelines for the best management of patients with prediabetes.

Perreault L. W22. Presented at: AACE 23rd Annual Scientific & Clinical Congress; May 13-18, 2014; Las Vegas, Nevada.  

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 May, 2014 and appeared in  CardiovascularIssue 730

Past five issues: SGLT-2 Inhibitors Special Edition October 2014 | Diabetes Clinical Mastery Series Issue 211 | Issue 751 | Humulin Insulin Special Edition October 2014 | Diabetes Clinical Mastery Series Issue 210 |

2014 Most Popular Articles:

FDA Approves Once-Weekly GLP-1 Diabetes Treatment Regimen for T2DM
Posted September 25, 2014
Stanley Schwartz, MD: A New Way of Classifying Diabetes - The Beta-Cell Centric Approach
Posted September 29, 2014
Two Positive Phase 3 Trials for ITCA 650 (Exenatide, a GLP-1 Agonist) in Type 2 Diabetes
Posted October 10, 2014
Best Insulin Regimen for Type 1's
Posted October 10, 2014
EASD: Insulin Pumps Lower Mortality Rate 29% Compared to Multiple Injections in T1DM
Posted October 03, 2014
GLP-1 Agonist Medications Chart
Posted September 23, 2014
Handbook of Diabetes, 4th Ed., Excerpt #13: Control and Complications
Posted October 13, 2014
Non-Caloric Artificial Sweeteners May Induce Glucose Intolerance
Posted October 10, 2014
New GLP-1 Receptor Agonist as an Alternative to Insulin Glargine?
Posted October 10, 2014
FDA Approves an Eye Drug for Diabetic Patients
Posted September 25, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do your teenage patients manage their diabetes well?
CME/CE of the Week
Marie Williams, DPM

Category: Wound Care
Credits: .75



Search Articles On Diabetes In Control